FDA Advisors Soundly Reject Anti-Blood Clotting Candidate Cangrelor

Drug Industry Daily
A A
FDA advisors Wednesday overwhelmingly recommended against approval of The Medicines Company’s anti-blood clotting drug candidate cangrelor.

To View This Article:

Login

Subscribe To Drug Industry Daily